`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE EASTERN DISTRICT OF TEXAS
`MARSHALL DIVISION
`
`
`§
`§
`§
`§
`§
`§
`§
`§
`§
` §
` §
` §
` §
` §
`
`
`ORDER
`Before the Court is Defendant Daiichi Sankyo Co., Ltd.’s (“DSC”) Unopposed Motion to
`
`
`
`
`
`
`CIVIL ACTION NO. 2:20-CV-00337-JRG
`
`
`
`
`
`
`SEAGEN INC.,
`
`
`
`v.
`
`DAIICHI SANKYO CO., LTD.,
`
`
`
`ASTRAZENECA PHARMACEUTICALS
`LP, and ASTRAZENECA UK LTD
`
`
`
`
`
`
`Plaintiff,
`
`
`
`
`
`Defendant,
`
`Intervenor-Defendants.
`
`
`
`Withdraw Defendant Daiichi Sankyo Japan’s Motion to Compel Seagen Inc.’s Discovery
`
`Production (Dkt. No. 221); Plaintiff Seagen Inc. (“Seagen”), DSC, and Defendant-Intervenors
`
`AstraZeneca Pharmaceuticals LP and AstraZeneca UK Ltd.’s (collectively, “AstraZeneca”)
`
`Unopposed Motion to Withdraw and Partially Withdraw Motions to Compel Regarding
`
`Depositions [Dkt.188 and 213] (Dkt. No. 223); Seagen, DSC, and AstraZeneca’s Unopposed
`
`Motion to Withdraw Motions to Compel Regarding Privilege Issues [Dkt. 201, 202, 211] (Dkt.
`
`No. 224); and Seagen, DSC, and AstraZeneca’s Unopposed Motion to Withdraw Seagen’s
`
`Renewed Motion to Compel Daiichi Sankyo Co., Ltd.’s Production of Development Documents
`
`and for Relief under Rule 37 [Dkt. 187] (Dkt. No. 225) (collectively, the “Motions to Withdraw”).
`
`Having considered the Motions to Withdraw, and noting their joint and unopposed nature, the
`
`Court is of the opinion that they should be and hereby are GRANTED.
`
`
`
`Case 2:20-cv-00337-JRG Document 227 Filed 11/12/21 Page 2 of 2 PageID #: 8509
`
`Accordingly, it is ORDERED that DSC’s Motion to Compel Seagen Inc.’s Discovery
`
`Production (Dkt. No. 179), Seagen’s Renewed Motion to Compel Daiichi Sankyo Co., Ltd.’s
`
`Production of Development Documents and for Relief under Rule 37 (Dkt. No. 187), Seagen’s
`
`Motion to Compel Daiichi Sankyo Co., Ltd to Produce Alleged Common Interest Agreement and
`
`Withheld Documents (Dkt. No. 201), Seagen’s Motion to Compel AstraZenca To Produce
`
`Responsive Communications with DSC and Other Documents over Which Privilege Claims Have
`
`Been Waived (Dkt. No. 202), AstraZeneca’s Motion to Compel Seagen to Produce Documents
`
`and Testimony over Which Privilege Has Been Waived (Dkt. No. 211), and AstraZeneca’s Motion
`
`to Compel Seagen to Produce Dr. Peter Senter’s Arbitration Testimony and Related Materials
`
`(Dkt. No. 213) are WITHDRAWN. Further, Seagen’s Motion to Compel Depositions of
`
`Toshinori Agatsuma, Yuki Abe, Yuji Kasuya, and Koji Morita (Dkt. No. 188) is PARTIALLY
`
`WITHDRAWN with respect to Toshinori Agatsuma, Yuki Abe, and Yuji Kasuya. The Court will
`
`issue a separate order resolving the remaining motions to compel as announced during the
`
`November 10, 2021 motions hearing.
`
`
`
`
`
`
`2
`
`So Ordered this
`Nov 12, 2021
`
`